|
1.
|
Pisani P, Parkin DM, Bray F and Ferlay J:
Estimates of the worldwide mortality from 25 cancers in 1990. Int J
Cancer. 83:870–873. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Alberts SR, Cervantes A and van de Velde
CJ: Gastric cancer: epidemiology, pathology and treatment. Ann
Oncol. 14(Suppl 2): ii31–ii36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Shibuya K, Mathers CD, Boschi-Pinto C,
Lopez AD and Murray CJ: Global and regional estimates of cancer
mortality and incidence by site: II. Results from the global burden
of disease 2000. BMC Cancer. 2:372002. View Article : Google Scholar
|
|
4.
|
Meads MB, Hazlehurst LA and Dalton WS: The
bone marrow microenvironment as a tumor sanctuary and contributor
to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Parmar K, Mauch P, Vergilio JA, Sackstein
R and Down JD: Distribution of hematopoietic stem cells in the bone
marrow according to regional hypoxia. Proc Natl Acad Sci USA.
104:5431–5436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Glimelius B, Ekström K, Hoffman K, et al:
Randomized comparison between chemotherapy plus best supportive
care with best supportive care in advanced gastric cancer. Ann
Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hill ME and Cunningham D: Medical
management of advanced gastric cancer. Cancer Treat Rev.
24:113–118. 1998. View Article : Google Scholar
|
|
8.
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
9.
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Petty RD, Nicolson MC, Kerr KM,
Collie-Duguid E and Murray GI: Gene expression profiling in
non-small cell lung cancer: from molecular mechanisms to clinical
application. Clin Cancer Res. 10:3237–3248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Stavrovskaya AA: Cellular mechanisms of
multidrug resistance of tumor cells. Biochemistry (Moscow).
65:95–106. 2000.PubMed/NCBI
|
|
12.
|
Banerjee D, Mayer-Kuckuk P, Capiaux G,
Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of
resistance to drugs targeted to dihydrofolate reductase and
thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Larsen AK, Escargueil AE and Skladanowski
A: Resistance mechanisms associated with altered intracellular
distribution of anticancer agents. Pharmacol Ther. 85:217–229.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ross DD: Novel mechanisms of drug
resistance in leukemia. Leukemia. 14:467–473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Litman T, Druley TE, Stein WD and Bates
SE: From MDR to MXR: New understanding of multidrug resistance
systems, their properties and clinical significance. Cell Mol Life
Sci. 58:931–959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Narasaki F, Oka M, Nakano R, Ikeda K,
Fukuda M, Nakamura T, Soda H, Nakagawa M, Kuwano M and Kohno S:
Human canalicular multispecific organic anion transporter (cMOAT)
is expressed in human lung, gastric, and colorectal cancer cells.
Biochem Biophys Res Commun. 240:606–611. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Nakamura T, Oka M, Aizawa K, Soda H,
Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, et al:
Direct interaction between a quinoline derivative, MS-209, and
multidrug resistance protein (MRP) in human gastric cancer cells.
Biochem Biophys Res Commun. 255:618–624. 1999. View Article : Google Scholar
|
|
18.
|
Tomonaga M, Oka M, Narasaki F, Fukuda M,
Nakano R, Takatani H, Ikeda K, Terashi K, Matsuo I, Soda H, et al:
The multidrug resistance-associated protein gene confers drug
resistance in human gastric and colon cancers. Jpn J Cancer Res.
87:1263–1270. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hao Z, Li X, Qiao T, Du R, Hong L and Fan
D: CIAPIN1 confers multidrug resistance by upregulating the
expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol
Ther. 5:261–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Maeda S, Sugiura T, Saikawa Y, Kubota T,
Otani Y, Kumai K and Kitajima M: Docetaxel enhances the
cytotoxicity of cisplatin to gastric cancer cells by modification
of intracellular platinum metabolism. Cancer Sci. 95:679–684. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Tang XQ, Bi H, Feng JQ and Cao JG: Effect
of curcumin on multidrug resistance in resistant human gastric
carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 26:1009–1016.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chen Y, Ji L, Wang H and Wang Z:
Intracellular glutathione plays important roles in pyrrolizidine
alkaloids-induced growth inhibition on hepatocytes. Environ Toxicol
Pharmacol. 28:357–362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kosower NS and Kosower EM: The glutathione
status of cells. Int Rev Cytol. 54:109–160. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Markman M: Antineoplastic agents in the
management of ovarian cancer: current status and emerging
therapeutic strategies. Trends Pharmacol Sci. 10:515–519. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Muggia F: Platinum compounds 30 years
after the introduction of cisplatin: implications for the treatment
of ovarian cancer. Gynecol Oncol. 112:275–281. 2009.PubMed/NCBI
|
|
26.
|
Lustberg MB and Edelman MJ: Optimal
duration of chemotherapy in advanced non-small cell lung cancer.
Curr Treat Options Oncol. 8:38–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Matthews GM, Howarth GS and Butler RN:
Nutrient and anti-oxidant modulation of apoptosis in gastric and
colon cancer cells. Cancer Biol Ther. 5:569–572. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Podder S, Chattopadhyay A, Bhattacharya S,
Ray MR and Chakraborty A: Fluoride-induced genotoxicity in mouse
bone marrow cells: effect of buthionine sulfoximine and
N-acetyl-L-cysteine. J Appl Toxicol. 31:618–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Beketić-Oresković L, Osmak M and Jaksić M:
Human larynx carcinoma cells resistant to
cis-diamminedichloroplatinum(II): mechanisms involved in the
resistance. Neoplasma. 41:163–169. 1994.
|
|
30.
|
Balendiran GK, Dabur R and Fraser D: The
role of glutathione in cancer. Cell Biochem Funct. 22:343–352.
2004. View
Article : Google Scholar
|
|
31.
|
Akiyama SI, Chen ZS, Sumizawa T and
Furukawa T: Resistance to cisplatin. Anticancer Drug Des.
14:143–151. 1999.
|
|
32.
|
Panasci L, Paiement JP, Christodoulopoulos
G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug
resistance in chronic lymphocytic leukemia: the emerging role of
DNA repair. Clin Cancer Res. 7:454–461. 2001.PubMed/NCBI
|
|
33.
|
Bredel M: Anticancer drug resistance in
primary human brain tumors. Brain Res Rev. 35:161–204. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Germann UA: P-glycoprotein - a modulator
of multidrug resistance in tumor cells (Review). Eur J Cancer.
32A:927–944. 1996. View Article : Google Scholar
|
|
35.
|
Müller M, Meijer C, Zaman GJ, et al:
Overexpression of the gene encoding the multidrug
resistance-associated protein results in increased ATP-dependent
glutathione S-conjugate transport. Proc Natl Acad Sci USA.
91:13033–13037. 1994.PubMed/NCBI
|
|
36.
|
Hipfner DR, Deeley RG and Cole SP:
Structural, mechanistic and clinical aspects of MRP1. Biochim
Biophys Acta. 1461:359–376. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Wang D and Lippard SJ: Cellular processing
of platinum anti-cancer drugs. Nat Rev Drug Discov. 4:307–320.
2005. View
Article : Google Scholar
|
|
39.
|
Kang YH, Lee E, Youk HJ, Kim SH, Lee HJ,
Park YG and Lim SJ: Potentiation by alpha-tocopheryl succinate of
the etoposide response in multidrug resistance protein 1-expressing
glioblastoma cells. Cancer Lett. 217:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Jin J, Huang M, Wei HL and Liu GT:
Mechanism of 5-fluorouracil required resistance in human
hepatocellular carcinoma cell line Bel(7402). World J
Gastroenterol. 8:1029–1034. 2002.PubMed/NCBI
|
|
41.
|
Xu BH and Singh SV: Effect of buthionine
sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin
C analogues BMY 25282 and BMY 25067. Cancer Res. 52:6666–6670.
1992.PubMed/NCBI
|
|
42.
|
Chen HH and Kuo MT: Role of glutathione in
the regulation of Cisplatin resistance in cancer chemotherapy. Met
Based Drugs 2010. pii:430–939. 2010.
|
|
43.
|
Akan I, Akan S, Akca H, Savas B and Ozben
T: Multidrug resistance-associated protein 1 (MRP1) mediated
vincristine resistance: effects of N-acetylcysteine and Buthionine
sulfoximine. Cancer Cell Int. 5:222005. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK
and Chen GF: Regulation of hypoxia inducible factor-1α expression
by the alteration of redox status in HepG2 cells. J Exp Clin Cancer
Res. 30:612011.
|
|
45.
|
Franco R and Cidlowski JA: Apoptosis and
glutathione: beyond an antioxidant. Cell Death Differ.
16:1303–1314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Akan I, Akan S, Akca H, Savas B and Ozben
T: N-acetylcysteine enhances multidrug resistance-associated
protein 1 mediated doxorubicin resistance. Eur J Clin Invest.
34:683–689. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Chuman Y, Chen ZS, Seto K, et al: Reversal
of MRP-mediated vincristine resistance in KB cells by buthionine
sulfoximine in combination with PAK-104P. Cancer Lett. 129:69–76.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Schafer FQ and Buettner GR: Redox
environment of the cell as viewed through the redox state of the
glutathione disulfide/glutathione couple. Free Radical Biol Med.
30:1191–1212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Commandeur JN, Stijntjes GJ and Vermeulen
NP: Enzymes and transport systems involved in the formation and
disposition of glutathione S-conjugates. Role in bioactivation and
detoxification mechanisms in xenobiotics. Pharmacol Rev.
47:271–330. 1995.PubMed/NCBI
|
|
50.
|
Benderra Z, Trussardi A, Morjani H, Villa
AM, Doglia SM and Manfait M: Regulation of cellular glutathione
modulates nuclear accumulation of daunorubicin in human MCF7 cells
overexpressing multidrug resistance associated protein. Eur J
Cancer. 36:428–434. 2000. View Article : Google Scholar
|
|
51.
|
Han YH, Moon HJ, You BR, Kim SZ, Kim SH
and Park WH: The effects of N-acetyl cysteine on the MG132
proteasome inhibitor-treated lung cancer cells in relation to cell
growth, reactive oxygen species and glutathione. Int J Mol Med.
25:657–62. 2010.PubMed/NCBI
|
